Q-omics provides the consensus-scored CRYBA4 profile across patient tissues and cancer cell-line models. CRYBA4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CRYBA4 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, CRYBA4 RNA expression shows 9,720 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, COAD, and TGCT as cancer lineages where CRYBA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYBA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYBA4 survival associations across molecular data types. CRYBA4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYBA4 RNA expression–survival associations across cancer types. High CRYBA4 expression shows unfavorable associations in COAD, KIRC and ACC, but favorable associations in SKCM, HNSC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CRYBA4 RNA expression.
This table summarizes CRYBA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CRYBA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYBA4 shows lower tumor expression in KIRP and KICH and higher tumor expression in COAD, BRCA and UCEC. The COAD box plot shows higher CRYBA4 RNA expression in tumor versus normal tissue (log2 FC = +0.544, t-test p < 0.001).
This table shows molecular features associated with CRYBA4 in patient tissues and cancer cell lines. In patient samples, CRYBA4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYBA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
